A
Participants and Invited Experts Between December 1, 2004, and June 27, 2005
Participants
December 1, 2004
Alan Breier
Vice President, Medical, and Chief Medical Officer
Eli Lilly and Company
Catherine D.DeAngelis
Editor-in-Chief
Journal of the American Medical Association
Jeffrey M.Drazen
Editor-in-Chief
New England Journal of Medicine
Lawrence Hirsch
Executive Director, Medical Communications
Merck Research Laboratories
Richard Kingham
Partner
Covington & Burling
Ronald Krall
Senior Vice President, World Wide Development, GlaxoSmithKline Pharmaceuticals
Alexa McCray
Director, Lister Hill National Center for Biomedical Communications
National Library of Medicine
Lana Skirboll (via phone)
Associate Director of Science Policy
Office of the Director
National Institutes of Health
Harold C.Sox
Editor
Annals of Internal Medicine
Melvyn L.Sterling
Chair, Council on Scientific Affairs
American Medical Association
Robert Temple (via phone)
Director, Office of Medical Policy
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Elias Zerhouni (via phone)
Director
National Institutes of Health
Invited Experts
Between December 1, 2004, and June 27, 2005
Alan Breier
Vice President, Medical and Chief Medical Officer
Eli Lilly and Company
Catherine D.DeAngelis
Editor-in-Chief
Journal of the American Medical Association
Jeffrey M.Drazen
Editor-in-Chief
New England Journal of Medicine
Lawrence Hirsch
Executive Director, Medical Communications
Merck Research Laboratories
John Hoey
Editor
Canadian Medical Association Journal
Christine Laine
Executive Secretary
Annals of Internal Medicine
Justin McCarthy
General Counsel, Pfizer Global Research and Development
Pfizer, Inc.
Frank Rockhold
Senior Vice President and Director, Biomedical Data Sciences
GlaxoSmithKline Pharmaceuticals Research and Development
Alfred Sandrock
Vice President, Medical Research-Neurology
Biogen Idec
Ralph Smalling
Vice President, Global Research and Development Policy Analysis
Amgen
Harold Sox
Editor
Annals of Internal Medicine